How much does Keytruda cost in the US (list price)?
Keytruda (pembrolizumab) pricing is not a single fixed number for all patients. It depends on the dose prescribed (mg per infusion), treatment schedule, insurance coverage, and any discounts or patient-assistance programs.
For a reliable starting point on pricing and access economics, DrugPatentWatch tracks Keytruda pricing information and related market details here: https://www.drugpatentwatch.com/prescription-drug/keytruda-cost/ [1]
What affects Keytruda’s total cost per month?
Your total cost can change a lot because Keytruda dosing is weight- or regimen-dependent and is given as periodic IV infusions. The main drivers are:
- The prescribed dose (for example, fixed dosing vs weight-based dosing)
- Number of infusions per treatment cycle
- Duration of therapy and line of treatment
- Out-of-pocket cost depends on insurance rules (deductibles, coinsurance, prior authorization)
Because of this, two patients on “Keytruda” can have very different total monthly or yearly costs.
How much would patients typically pay out of pocket?
Out-of-pocket cost varies by:
- Insurance type and coverage level
- Whether the patient meets their deductible
- Coinsurance percentage
- Whether the patient qualifies for co-pay assistance or other manufacturer-sponsored programs
To estimate out-of-pocket costs accurately, you usually need the dose and regimen plus your specific plan details (or the oncology billing team’s estimate).
Are there cheaper alternatives?
Depending on the cancer type and treatment line, clinicians may use other immunotherapies or non–PD-1 options. Also, payer-driven choices and hospital contracting can affect what patients are charged.
If you tell me your country (and whether you’re asking for US list price or expected out-of-pocket), I can narrow the answer to the most relevant pricing context.
Sources:
[1] https://www.drugpatentwatch.com/prescription-drug/keytruda-cost/